博雅生物(300294) - 2018年8月17日投资者关系活动记录表

Financial Performance - The company achieved total revenue of ¥1,092,286,202.46, representing a year-on-year growth of 102.11% [2] - Operating profit reached ¥224,938,481.95, with a year-on-year increase of 18.16% [4] - Net profit attributable to ordinary shareholders was ¥190,963,229.96, reflecting a growth of 21.07% compared to the previous year [4] Business Development - Blood product and non-blood product businesses maintained stable growth [4] - The company has established a professional sales team of over 100 members, which has significantly boosted sales in the blood product sector [4] - Sales are primarily concentrated in East and Central China, with weaker performance in South China [4] Market Trends - The estimated national plasma collection for 2018 is 8,800 tons, with a growth of 10% [6] - The company currently operates 12 plasma collection stations, with potential to achieve over 400 tons of collection [6] - The price of albumin and immunoglobulin has decreased by 5-10% year-on-year, while the price of fibrinogen has remained stable [6] Regulatory and Certification Updates - The company has completed internal rectification for GMP certification and is awaiting inspection by relevant authorities [7] - Plasma allocation has received approval from Jiangxi and Guangdong drug regulatory authorities, pending national approval [7] Sales and Marketing Strategy - The sales expense ratio has remained stable compared to 2017, with no significant increase expected [5] - Academic promotion efforts are focused on foundational work rather than new indications for products [5]